Specific scientific goals of the Personalised Health Care initiative will be to produce patient-matched tissues and organs to overcome the shortage of organs for transplant and associated immunosuppression; the regeneration or enhancement of organs and tissues in the body; and the development of targeted and specific therapies for age-related diseases. It will also increase awareness and acceptance among the population of new technologies such as gene editing and gene therapy, optogenetics and stem cells, and cope with the regulatory framework, marketing and cost of the new advanced therapies being developed.
FET Flagships are one of the most prestigious, highly-funded, strongest and game-changing instruments of EU research, with a total budget of about €1billion. So far only two FET Flagships have been approved: Graphene and the Human Brain Project. If successful in the 2018 call, Personalised Health Care will be expected to run for about 10 years under the next framework program, FP9.
For more information, check out the Personalised Health Care Initiative in Europe website here.
